BioSpace News Archive

Medicine Man Technologies, Inc. (OTCQX: MDCL) (“Medicine Man Technologies” or “the Company”) today provided a company update and announced financial results for its fourth quarter and full year 2019.

Axiom Real-Time Metrics (“Axiom”), premier provider of unified eClinical solutions and services is responding to the unique and unprecedented circumstances the COVID-19 global pandemic.

Supernus Pharmaceuticals, Inc., a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, provides a business update related to the COVID-19 situation.

Exicure, Inc. provided an update on the Company’s operations in response to the global COVID-19 pandemic and the Company’s current evaluation of the impact the pandemic may have on the Company’s clinical trials, preclinical research and development and general business operations.

Mind Medicine Inc. announced the release of its audited consolidated financial statements and accompanying management’s discussion and analysis for the period from May 30, 2019, date of incorporation, to December 31, 2019.

Amarin Corporation plc commented on the United States District Court for the District of Nevada’s ruling in favor of the generic companies in the company’s patent litigation against two filers of abbreviated new drug applications, or ANDAs, for Amarin’s VASCEPA® capsule franchise.

AgeX Therapeutics, Inc. (“AgeX”; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and year-end results for 2019.

Junshi Biosciences announced the approval of its proposed A-share listing by the Listing Committee for the Shanghai Stock Exchange STAR Market.

Viva Biotech Holdings announced its annual results for the twelve months ended 31 December 2019.

Results from a sub-study of 70 patients with end-stage ischemic heart failure and a Left Ventricular Assist Device, of 159 randomized patients who received either Mesoblast’s allogeneic mesenchymal precursor cell product candidate Revascor® or saline, were presented on March 28 at the American College of Cardiology Virtual Scientific Sessions.